Barings LLC increased its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 92.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,860 shares of the biopharmaceutical company’s stock after purchasing an additional 2,820 shares during the quarter. Barings LLC’s holdings in Alexion Pharmaceuticals were worth $822,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Fiduciary Trust Co. bought a new stake in Alexion Pharmaceuticals during the second quarter worth $111,000. Penserra Capital Management LLC raised its position in Alexion Pharmaceuticals by 13.0% during the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 144 shares in the last quarter. Dupont Capital Management Corp bought a new stake in Alexion Pharmaceuticals during the third quarter worth $156,000. Acadian Asset Management LLC bought a new stake in Alexion Pharmaceuticals during the second quarter worth $160,000. Finally, BT Investment Management Ltd bought a new stake in Alexion Pharmaceuticals during the third quarter worth $165,000. Institutional investors and hedge funds own 94.16% of the company’s stock.
Several analysts have issued reports on ALXN shares. BidaskClub lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th. Evercore ISI started coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, August 16th. They set an “in-line” rating and a $137.00 price target on the stock. J P Morgan Chase & Co raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $163.00 to $175.00 in a research report on Tuesday, September 5th. BMO Capital Markets reaffirmed an “outperform” rating and set a $173.00 price target (up from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $180.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $155.06.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company’s revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.23 earnings per share. sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current fiscal year.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.